Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-08-17
2000-02-29
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544284, 544285, 544286, 544287, 544288, 544290, 544116, 544 73, 544 92, 544 93, 544 50, 544253, 544254, 5442305, 5442242, A61K 31505, C07D23991, C07D23992, C07D26522, C07D27908
Patent
active
060309733
ABSTRACT:
The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their analogues, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinediones of the general formula (I), their analogues, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##
REFERENCES:
patent: 4873255 (1989-10-01), Yoshioka
patent: 5002953 (1991-03-01), Hindley
patent: 5037842 (1991-08-01), Goldstein
patent: 5468762 (1995-11-01), Malamas
patent: 5478851 (1995-12-01), Cantello
patent: 5478852 (1995-12-01), Olefsky
patent: 5478853 (1995-12-01), Regnier
patent: 5521201 (1996-05-01), Hindley
patent: 5710152 (1998-01-01), Nagao et al.
patent: 5885997 (1999-03-01), Lohray et al.
M. Modan, et al., J. Clin. Invest. (1985) vol. 75, pp. 809-817.
O. G. Kolterman, et al., J. Clin. Invest. (1981) vol. 68, pp. 957-969.
E. Ferrannini, et al., The New England Journal of Medicine (1987) vol. 317, pp. 350-357.
D.C. Shen, et al., J. Clin. Endocrinol. Metab. (1988) vol. 66, pp. 580-583.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Ediition, pp. 1496-1497.
Clifford Bailey, "Potential New Treatments for Type 2 Diabetes", Chemistry & Industry, Jan. 19, 1998, pp. 53-57.
T. Antonucci, et al., "Imparied Glucose Tolerance is Normalized by Treatment with the ThiazolidinedioneTroglitazone" Diabetes Care, vol. 20, No. 2, Feb. 1997, pp. 188-193.
Messier, C. et al., Behavioral Brain Research, 75 (1966) 1-11.
Sohda, T. et al., Chem Pharm Bull. 30, 10 (1982), 3580-3600.
Clark, et al. J. Med. Chem 34 (1991) 319-325.
Dow, R. L. et al., J. Med. Chem 34 (1991) 1538-1544.
Hulin, et al., J. Med. Chem 35 (1992) 1853-1864.
Sohda, T. et al., J. Med. Chem 35 (1992) 2617-2626.
Goldstein, et al., J. Med. Chem. 36 (1993) 2238-2240.
Cantello, et al., J. Med. Chem 37 (1994) 3977-3985.
English Translation of JP-A-0912575.
Husain M.I. et al: "Some New 2-Aryloxymethyl-3-Alpha-Substituted Carboxymethyl-6, 8-Substituted 4-Quinazolones as Possible Anticonvulsants" Pharmazie, vol. 37, No. 6, 1982, pp. 408-410, XP002045115.
Chakrabarti Ranjan
Lohray Braj Bhushan
Lohray Vidya Bhushan
Paraselli Rao Bheema
Ramanujam Rajagopalan
Dr. Reddy's Research Foundation
Kessinger Ann M.
Reddy-Cheminor Inc.
Shah Mukund J.
LandOfFree
Heterocyclic compounds having antidiabetic hypolipidemia and ant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds having antidiabetic hypolipidemia and ant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds having antidiabetic hypolipidemia and ant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-683269